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Background: Cardioembolic stroke is an under-recognized complication in patients with limb-girdle muscular
dystrophy 1B. Here we present a young stroke patient who had a novel lamin A/C gene (LMNA) mutation.
Case presentation: This is a 39-year-old man who had slowly progressive proximal muscle weakness and cardiac
arrhythmia since adolescent and a family history of similar manifestation. He sustained acute ischemic stroke in the
left middle cerebral artery territory. Intravenous recombinant tissue plasminogen activator therapy was given with
significant neurological improvement. Additionally, genetic sequencing of the LMNA gene of the patient identified
a mutation in c.513+1 G>A that resulted in a splicing aberration.
Conclusion: We suggested that LMNA gene related myopathies should be considered in young stroke patients
with long-standing myopathic features.
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Limb-girdle muscular dystrophy 1B (LGMD1B) is an
autosomal dominant muscular dystrophy caused by a
lamin A/C gene (LMNA) mutation, and is characterized
by slowly progressive proximal weakness with few con-
tractures and age-related cardiac arrhythmias. The
LMNA gene is located on chromosome 1q21.1–21.2 and
comprises 12 exons consisting of a 25 KB coding region
of the gene [1,2]. The LMNA gene encodes lamins A
and C, which are components of the nuclear envelope
but are located in the lamina, a multimeric structure
associated with the nucleoplasmic surface of the inner
nuclear membrane. Lamins are structurally homologous
with other intermediate filaments, and are expressed in
a wide range of tissues, including adult heart and skeletal
muscle [3].
Mutations of the LMNA gene are associated with mul-
tiple allelic diseases with widely varying phenotypes, in-
cluding autosomal dominant dilated cardiomyopathy with
conduction defects (DCM-CD), AD-EDMD, LGMD1B,
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Hutchinson–Gilford progeria, and atypical Werner syn-
drome (Table 1) [4-6] The skeletal muscle phenotypes of
laminopathy, namely autosomal dominant Emery-Dreifuss
muscular dystrophy (AD-EDMD) and LGMD1B, are over-
lapping syndromes exhibiting greater or lesser degrees of
muscle weakness, joint contractures and cardiac dysfunc-
tion [7,8]. Dilated cardiomyopathy with conduction
defects and arrhythmias requiring pacemaker placement
affect both groups of patients. Thus, cardioembolic stroke
is a severe but rarely reported complication [4].
Here we present a case of a young stroke patient with
long lasting myopathic features which prompted the de-
tection of a novel LMNA mutation. Intravenous admin-
istration of recombinant tissue plasminogen activator
(rt-PA) successfully improved his initial severe neuro-
logical disability.
Case presentation
The patient was a 39-year-old man, who was the first of
2 siblings. His mother had a history of slowly progressive
proximal muscle weakness, received pacemaker implant-
ation for slow heart rate at the age of 40 years, and died
from sudden cardiac arrest at the age of 50. His younger
brother also had similar proximal lower limbs weakness;td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 List of important diseases caused by mutations
of the LMNA gene
































AD autosomal dominant, AR autosomal recessive.
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index patient, toe-walking and frequent falls were first
noted at the age of around 5 years. In his adolescence,
he developed proximal leg weakness with Gowers’ sign
(i.e., with hip girdle weakness, the patient arises from a
stooped or a squatting position by using his hands to
“climb up the legs”). Around age 30 years, atrial fibrilla-
tion (AF) was found, and he was prescribed with aspirin
and an angiotensin-converting enzymes inhibitor. In
addition, mild ankle contractures were noted. An elec-
tromyographic study revealed myopathic changes, con-
sisting of muscle potentials of small amplitudes and
polyphasic waves of short duration, in biceps brachii and
rectus femoris. His baseline creatine kinase level was
around 200 IU/L (reference range, <190 IU/L for a
male). At age 36 years, he complained of chest tightness,
and electrocardiography showed AF with slow ventricu-
lar rate, right bundle branch block, and transient ven-
tricular tachycardia. Pacemaker implantation (VVI
pacemaker, i.e., ventricular pacing, ventricular sensing,
pacemaker inhibited) was done at that time.
He suffered from acute onset of right limb weakness
and speech disturbance. The acute onset of focal neuro-
logical symptoms was suggestive of stroke, thus he was
sent to our hospital immediately. Neurological examin-
ation revealed global aphasia, right hemianopia, gaze de-
viation to the left side, and right hemiplegia. TheNational Institutes of Health Stroke Scale (NIHSS) score
was 22. Initial head computed tomography (CT) did not
reveal intracranial hemorrhage. He received intravenous
thrombolytic therapy of recombinant tissue plasminogen
activator (rt-PA) (73 mg, equal to 0.9 mg/kg) within
3 hours of stroke onset. CT angiography right after
thrombolytic therapy revealed nearly total occlusion of
the left distal internal carotid artery and proximal middle
cerebral artery (MCA) (Figure 1a and b), and CT perfu-
sion image revealed reduced cerebral perfusion in the
left hemisphere (Figure 1c and d). Follow-up head CT
on the next day showed a hypodensity lesion mainly in
the left MCA territory (Figure 1e and 1f), and the size
was much smaller than the previous perfusion defect.
Transcranial color-coded sonography showed a visible
MCA flow signal on color mode but mildly reduced flow
velocity on Doppler mode, indicating partial recanaliza-
tion. Two-dimensional echocardiography revealed a left
ventricular ejection fraction of 47%, and enlargement of
bilateral ventricles and left atrium. Twenty-four hours
after thrombolytic therapy, his NIHSS score was 16; one
week later the NIHSS score significantly improved to 5.
He was treated with an oral anticoagulantion for second-
ary stroke prevention. After rehabilitation, his right
hemiplegia and aphasia improved gradually. Six months
after stroke, he could ambulate without assistance, and
speak fluently with only mild naming difficulty.
Given the myopathic features with mild contracture,
cardiac arrhythmia and dilated cardiomyopathy, and also
positive family history, LMNA related muscular dystro-
phies was highly suspected. For further genetic analysis,
the patient’s peripheral blood was obtained with informed
consent. All the coding and flanking regions of the LMNA
gene were amplified by polymerase chain reaction with
primers. The confirmatory sequencing demonstrated a
heterozygous mutation of “G” to “A” transition at the spli-
cing donor site at intron 2 (c.513+1 G>A / wild type,
Figure 2). The nucleoside change was not identified in
screening 50 Taiwanese controls. All the study subjects
had signed informed consent and the study protocol
was approved by the National Taiwan University Hos-
pital ethics board committees.
Discussion and conclusions
Mutations in the LMNA gene cause a variety of human
disease with numerous different phenotypes [4-6]. The
skeletal muscle phenotypes of AD-EDMD and LGMD1B
overlap. Both diseases are inherited in an autosomal
dominant fashion and express as slowly progressive
proximal limb weakness. AD-EDMD has more prominent
muscle wasting in humero-peroneal distribution, early
contractures of the elbow flexors, Achilles tendons and
rigid cervical spine, and has lethal cardiac arrhythmia that
requires pacemaker insertion. The cardiac involvement of
Figure 1 CT imaging of the patient. (a, b) Reconstructed CT angiography revealed nearly total occlusion of left proximal middle cerebral artery
(marked by the arrows). (c, d) CT perfusion study showed prolonged mean transit time (the blue area indicates the area of prolonged transit
time) in most of the left cerebral hemisphere, which indicated reduced perfusion. (e, f) Follow-up non-contrast CT one day after the stroke
showed a hypodensity in the left basal ganglia and peri-sylvian area, suggestive of a recent infarct. The size was much smaller than the previous
perfusion defect.
Figure 2 The results of genetic sequencing of the LMNA gene.
In this electropherogram, the green line represents adenine (A), the
blue line represents cytosine (C), the black line represents guanine
(G), and the red line represents thymine (T). Compared with the wild
type (WT, the lower part), our patient carries a heterozygous
mutation of “G” to “A” transition at intron 2 (c.513+1 G>A, the
upper part).
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presentation without detectable skeletal muscle manifest-
ation [8]. On the other hand, LGMD1B has typical girdle
weakness, absent or minimal contractures, and has age-
related severity of atrioventricular conduction distur-
bances. The neuromuscular symptomatology almost
always precedes cardiological involvement in LGMD1B
[9]. Therefore, our patient should be classified as having
LGMD1B based on less contractures and age-related car-
diac conduction disturbance.
Ischemic stroke of cardioembolic origin is a relatively
rare but severe complication among patients of myop-
athy and cardiac arrhythmia. In a literature review, the
prevalence of AF or atrial flutter in patients with pri-
mary myopathies was estimated as 15% [10]. The most
frequently reported myopathies that are associated with
arrhythmia included myotonic dystrophy, EDMD, dys-
trophinopathies, and limb girdle muscular dystrophies.
The stroke rate in patients with myopathy and AF/atrial
flutter was around 6.5%, and most of them received oral
anticoagulant for secondary stroke prevention [10].
Limited data are available about the incidence of
stroke in laminopathy, namely AD-EDMD or LGMD 1B.
We reviewed the published literature and found 7 previ-
ously reported cases (Table 2) [4,11-14]. All are ischemic
strokes, and all except our patient are characterized by
the AD-EDMD phenotype. Most of the patients suffered













Onishi et al., 2002 [11] 45 Right hemiplegia N/A AF, AVB, VPC Pacemaker, 45 AD-EDMD p.Ser303Pro (c.907 T>C)
Boriani et al., 2003 [4] 26 Hemiplegia N/A AF, AFL, AVB VVI, 30 AD-EDMD p.Arg386Lys (c.1157 G>A)
57 and 70 N/A N/A AF, AVB, SAB VVI, 55 AD-EDMD p.Arg527Pro (c.1580 G>C)
43 and 44 Ataxia Cerebellum AF, AVB VVI, 41 AD-EDMD p.Arg377Leu (c.1130 G>T)
Liang et al., 2007 [12] 45 Conscious loss Pons VPC, VT, VF nil AD-EDMD p.Trp520Gly (c.1558 T>G)
Redondo-Vergé et al.,
2011 [13]
25 Aphasia, right hemiparesis Left MCA AF, AVB ICD, 25 AD-EDMD p.Arg89Leu (c.266 G>T)
Tanaka et al., 2012 [14] 12 Dysarthria, left hemiparesis Right MCA AF nil AD-EDMD N/A
Present case 39 Aphasia, right hemiplegia Left MCA AF, RBBB, AVB VVI, 37 LGMD1B c.IVS2+1 G>A
(c.513+1 G>A)
AF atrial fibrillation, AVB atrioventricular block, ICD implantable cardioverter defibrillator, MCA middle cerebral artery, N/A non available, SAB sinoatrial block, VPC
ventricular paroxysmal contraction, VT ventricular tachycardia.
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old). All had documented cardiac arrhythmias (usually AF
and atrioventricular conduction block), and many of them
had received pacemaker or implantable cardioverter-
defibrillator (ICD) insertion. Thus, although no current
guidelines are available, oral anticoagulant is advisable in
such cases with AF for stroke prevention. Pacemaker or
ICD implantation should be considered as soon as brady-
cardia or ventricular tachyarrhythmia occurs, even as a
primary prevention method, to reduce the risk of sudden
death [15].
To date, more than 300 mutations have been reported
in LMNA gene (based on an on-line database: www.UMD.
be/LMNA/). A novel mutation in c.513+1 G>A was iden-
tified from our index patient. Although the mutation does
not affect the coding region, its position is in the splice
donor site of intron 2. We speculate this splicing donor
site mutation may be associated with abnormal splicing
process. One German pedigree was reported to have a
synonymous codon change of LMNA gene in c.513 G>A,
resulting in a so-called “neutral” mutation of Lys171Lys,
which leads to abnormal splicing of intron 2 and possibly
causes LGMD1B [16]. In addition, another family of
LGMD1B had a mutation in the splice donor site of intron
9 (IVS9+5 G>C), which also leads to abnormal splicing of
LMNA mRNA [17]. Therefore, our case probably had a
disease-causing mutation in the intron, which leads to
abnormal splicing of LMNA gene and mutant lamin
production.
In conclusion, we presented a LGMD1B patient with
proven LMNA gene mutation who suffered from disabling
cardioembolic stroke, and was treated effectively with
intravenous thrombolytic therapy. When a suspected car-
dioembolic stroke occurring at a relatively young age is
associated with long-standing myopathic features, LMNA
gene related disorders should be considered.Consent
Written informed consent was obtained from the patient
and his wife for publication of this Case report, any ac-
companying images, and the included family informa-
tion. A copy of the written consent is available for
review by the Series Editor of this journal.
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